-
Congenital Anomalies Sep 2005The objectives of the study was to check the embryotoxic-teratogenic and fetotoxic effect of mebendazole (Vermox; Richter, Budapest, Hungary) treatment during pregnancy.... (Comparative Study)
Comparative Study
The objectives of the study was to check the embryotoxic-teratogenic and fetotoxic effect of mebendazole (Vermox; Richter, Budapest, Hungary) treatment during pregnancy. Mebendazole use during pregnancy was evaluated in mothers of babies born with congenital abnormalities and in matched control mothers of babies born without congenital abnormalities in the population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996. Of 22,843 women who had newborns or fetuses with congenital abnormalities, 14 were found to have been treated with mebendazole for intestinal nematoda infections/diseases during pregnancy (crude POR: 1.8 with 95% CI: 0.7-4.2). Of 38,151 women who had newborns without any defects (controls), the same number (14) were found to have been treated with mebendazole during pregnancy. Six different congenital abnormality groups were evaluated and a higher prevalence of mebendazole use in these mothers throughout pregnancy was not found. Gestational age and birth weight were analyzed in control infants born to mothers with or without mebendazole treatment. The mean gestational age was somewhat longer and mean birth weight was larger in newborn infants born to mothers with mebendazole treatment. Thus, treatment with mebendazole during pregnancy did not indicate a teratogenic and fetotoxic risk to the embryo or fetus, though the numbers of treated cases and controls in this study were limited.
Topics: Abnormalities, Drug-Induced; Birth Weight; Case-Control Studies; Female; Gestational Age; Humans; Infant, Newborn; Maternal-Fetal Exchange; Mebendazole; Population Surveillance; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Teratogens
PubMed: 16131365
DOI: 10.1111/j.1741-4520.2005.00072.x -
The American Journal of Tropical... Sep 1983A patient with an Echinococcus granulosus cyst of the liver was treated with mebendazole for 94 days before operation. The serum levels of mebendazole varied from...
A patient with an Echinococcus granulosus cyst of the liver was treated with mebendazole for 94 days before operation. The serum levels of mebendazole varied from 39.4-274 ng/ml. After operation, cyst materials were inoculated into mice which developed hydatid cysts 10 months later. Intestinal absorption of mebendazole is poor and variable, and determination of serum concentrations is necessary during treatment. No apparently successful cases of drug treatment of E. granulosus infection have been verified by animal inoculation of cyst material; therefore, surgery must still be considered the treatment of choice. It is recommended that mebendazole be given prophylactically to prevent spread of the disease at operation.
Topics: Adult; Animals; Benzimidazoles; Combined Modality Therapy; Echinococcosis, Hepatic; Female; Humans; Mebendazole; Mice
PubMed: 6625063
DOI: 10.4269/ajtmh.1983.32.1071 -
Transactions of the Royal Society of... 1988
Topics: Animals; Female; Mebendazole; Mice; Schistosomiasis mansoni
PubMed: 3151527
DOI: 10.1016/0035-9203(88)90023-5 -
British Journal of Clinical Pharmacology Jan 1985Four different dose forms of mebendazole were administered to human volunteers, and urine was collected and assayed for mebendazole and unconjugated metabolites of...
Four different dose forms of mebendazole were administered to human volunteers, and urine was collected and assayed for mebendazole and unconjugated metabolites of mebendazole. Oral administration of mebendazole as an oily suspension slightly enhances the bioavailability of the drug, however mebendazole is not absorbed following rectal administration. The major urinary metabolite of mebendazole in humans is 2-amino-5(6)[alpha-hydroxybenzyl]benzimidazole (IV), not 2-amino-5(6) benzoylbenzimidazole (II), as previously reported.
Topics: Administration, Oral; Adult; Benzimidazoles; Biological Availability; Capsules; Humans; Male; Mebendazole; Suppositories; Tablets
PubMed: 3978024
DOI: 10.1111/j.1365-2125.1985.tb02617.x -
Veterinary Parasitology Apr 2024We evaluated the effect of 4 anthelmintic treatments on the viability of Trichinella spiralis encysted muscle larvae (ML) 55 days post infection (PI) in experimentally...
We evaluated the effect of 4 anthelmintic treatments on the viability of Trichinella spiralis encysted muscle larvae (ML) 55 days post infection (PI) in experimentally infected pigs. Muscle larvae were isolated from pig muscle by artificial digestion after oral treatment of pigs with Levamisole (8 mg/kg, daily for 5 days) and Mebendazole (50 mg/kg, daily for 5 days); Doramectin (0.3 mg/kg, single IM injection), and Moxidectin (0.5 mg/kg, single pour on). Isolated larvae from treated pigs were orally inoculated into mice to assess viability of ML from each treatment. Only Mebendazole treatment of pigs significantly reduced ML viability in mice. The effect of timing of the effective Mebendazole treatment on ML from a longer term infection was then examined in a second experiment. Analysis revealed that Mebendazole treatment of pigs with 250 mg/kg over 3 days (83 mg/kg/day) or 5 days (50 mg/kg/day) reduced numbers of ML recovered from pig tissues compared to untreated, infected controls, and rendered ML non-infective to mice; Mebendazole treatment of pigs with 250 mg/kg in a single dose was not effective in reducing ML numbers recovered from pigs or in impacting ML infectivity to mice. An examination of the lowest effective dose of Mebendazole on encysted ML was determined in a third experiment. Mebendazole of pigs with 5, 50, or 100 mg/kg over 3 days demonstrated that 5 or 50 mg/kg over 3 days insufficient to reduce infectivity in recovered ML, while 100 mg/kg (and 83 g from experiment 2) over 3 days significantly reduces infectivity of ML. This procedure provides a means to evaluate the efficacy of various anthelmintic treatments on the viability of Trichinella spiralis ML in pig tissues, and identified Mebendazole, at 83-100 mg/kg administered over a 3-5 day period as an anthelmintic which renders encysted Trichinella spiralis ML from pig tissues non-infective. As risk from Trichinella significantly impacts acceptance of pork from pasture-raised pigs, these data provide a method, especially for producers of these high-risk pigs, to eliminate the potential of Trichinella transmission from infected pork.
Topics: Swine; Mice; Animals; Trichinella spiralis; Mebendazole; Trichinellosis; Larva; Trichinella; Muscles; Anthelmintics; Rodent Diseases
PubMed: 38330532
DOI: 10.1016/j.vetpar.2024.110140 -
Acta Clinica Belgica 1977
Topics: Adult; Benzimidazoles; Drug Evaluation; Female; Humans; Male; Mebendazole; Middle Aged; Trichinellosis
PubMed: 610307
DOI: 10.1080/17843286.1977.11717878 -
The American Journal of the Medical... Jun 2007Intestinal parasites are difficult to eradicate in tropical climates where poor sanitation exists. In addition, pharmaceutical stability is poor making traditional three... (Clinical Trial)
Clinical Trial
BACKGROUND
Intestinal parasites are difficult to eradicate in tropical climates where poor sanitation exists. In addition, pharmaceutical stability is poor making traditional three day dosing for the treatment of A. lumricoides challenging.
METHODS
Single 100 mg doses of mebendazole were administered to persons living along Amazon tributaries in Northeastern Peru. Directly-observed treatment was repeated at 3-month intervals over a 2-year period in a single treatment village. Treatment was repeated at 12-month intervals in the remaining (control) villages. Treatment was accompanied by a regimen of multivitamins with iron to be taken daily for 14 days after each treatment. Subjects were screened for ova and parasites prior to treatment and at 1-year intervals. In addition to A. lumbricoides, other parasites found on screening were recorded.
RESULTS
Treatment resulted in a 92.5% cure rate for A. lumbricoides at the 2-year assessment. Growth and development assessments demonstrated fewer individuals below the 3 percentile for age-adjusted measurements when treated quarterly.
CONCLUSIONS
Based on these limited data, single low-dose mebendazole administered quarterly appears to have a positive effect on the health of isolated village populations in the Amazon River basin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amazona; Animals; Antinematodal Agents; Ascariasis; Ascaris lumbricoides; Child; Child, Preschool; Clinical Protocols; Drug Administration Schedule; Female; Humans; Infant; Male; Mebendazole; Middle Aged; Parasite Egg Count; Peru
PubMed: 17570986
DOI: 10.1097/MAJ.0b013e318065bafb -
European Journal of Drug Metabolism and... 1983The metabolism and pharmacokinetics of mebendazole was studied in rats using [2'-3H]-mebendazole (biologically stable; specific activity 383.9 (mCi/mMol) and...
The metabolism and pharmacokinetics of mebendazole was studied in rats using [2'-3H]-mebendazole (biologically stable; specific activity 383.9 (mCi/mMol) and [2-14C]-mebendazole (specific activity 2.57 mCi/mMol). Analyses were performed by high pressure liquid chromatography and liquid scintillation spectrometry. About 85% of an intravenous dose was eliminated with the bile and the remainder with the urine. The majority of the dose was recovered as conjugated metabolites. The major metabolite (methyl-5(6)-(alpha-hydroxybenzyl)-2-benzimidazole carbamate) accounted for about 77% of the total recovered and 99% of it was conjugated. Anaerobic metabolism studies conducted in vitro with intestinal microorganisms obtained from rats indicated that metabolism of mebendazole did not occur in the gut, but that the intestinal microflora was able to hydrolyse conjugated metabolites which were eliminated with the bile. Mebendazole was found to have a biphasic elimination profile after intravenous administration. Its terminal plasma elimination half-life was 3.2 hours and its re-distribution half-life was 0.4 hour. After oral administration, as a solution in aqueous dimethyl sulphoxide, a bioavailability of 53% was obtained.
Topics: Administration, Oral; Animals; Benzimidazoles; Bile; Biological Availability; Biotransformation; Chromatography, High Pressure Liquid; Injections, Intravenous; Intestinal Absorption; Intestines; Kinetics; Mebendazole; Rats
PubMed: 6673974
DOI: 10.1007/BF03188769 -
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng... Dec 2009Mebendazole is currently used in the treatment of hydatid disease. Its poor absorption from the gastrointestinal tract and low bioavailability aroused further research... (Review)
Review
Mebendazole is currently used in the treatment of hydatid disease. Its poor absorption from the gastrointestinal tract and low bioavailability aroused further research on new formulations of mebendazole to increase the bioavailability and improve the therapeutic efficacy. This review summarizes the recent research progress.
Topics: Animals; Anthelmintics; Biological Availability; Echinococcosis; Humans; Mebendazole
PubMed: 20232637
DOI: No ID Found -
Expert Review of Anti-infective Therapy Mar 2009
Review
Topics: Albendazole; Animals; Anthelmintics; Benzimidazoles; Clinical Protocols; Consensus; Echinococcosis; Echinococcus granulosus; Echinococcus multilocularis; Humans; Mebendazole
PubMed: 19254162
DOI: 10.1586/14787210.7.2.145